Title:
ＦＡＰ活性化治療剤及びそれに関連する使用
Document Type and Number:
Japanese Patent JP7093912
Kind Code:
B2
Abstract:
Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP - expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis and inflammation.
Inventors:
William W Bachovtin
Hun-Senrai
David Gee Sanford
Sara Epoplauski
Wengen Wu
Hun-Senrai
David Gee Sanford
Sara Epoplauski
Wengen Wu
Application Number:
JP2020130483A
Publication Date:
July 01, 2022
Filing Date:
July 31, 2020
Export Citation:
Assignee:
Bach BioSciences, LLC
International Classes:
A61K47/64; A61K9/08; A61K9/14; A61K9/19; A61K31/704; A61K47/65; A61P35/00
Domestic Patent References:
| JP6744826B2 | ||||
| JP2003500417A | ||||
| JP2008517917A |
Foreign References:
| WO2013033396A1 | ||||
| WO2002038590A1 |
Attorney, Agent or Firm:
Yanagida Seishi